Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120651 | 0.82 | KDM4E (0.40) | ADORA2AADORA1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL3372137 | 0.79 | GRIN1 (0.39) | ADORA2AADORA1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL1056459 | 0.79 | KDM4E (0.39) | ADORA2AADORA1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL10105623 | 0.77 | KDM4E (0.34) | ADORA2AADORA1CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL354152 | 0.76 | NNMT (0.45) | CYP2C9CYP1A2CYP2C19KDM4EPOLB | |
| SCHEMBL1823085 | 0.74 | GABRP (0.46) | KDM4EPOLBALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1822851 | 0.73 | KDM4E (0.40) | CYP2C9CYP1A2CYP2C19LMNAKDM4E | |
| SCHEMBL1128949 | 0.73 | KDM4E (0.44) | KDM4EPOLBALDH1A1MAPTMEN1 | |
| Hydrochloric Acid SCHEMBL1822852 | 0.73 | GABRP (0.45) | LMNAKDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL10120648 | 0.72 | KDM4E (0.39) | ADORA2AADORA1CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643310-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc (US) | 2013-10-02 | — | — | EP | disclosed |
| US-8513265-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-20 | — | — | US | disclosed |
| US-20130116237-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-09 | — | — | US | disclosed |
| US-8314095-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120202790-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| WO-2012069948-A1 | 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS | PFIZER INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2144902-B1 | [6,6]AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2438051-A1 | L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-04-11 | — | — | EP | disclosed |
| US-8076322-B2 | [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-13 | — | — | US | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286816-A1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286816-A1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286816-A1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| CN-101484441-A | Modulators of metabolism and the treatment of disorders related thereto | ARENA PHARM INC (US) | 2009-07-15 | — | — | CN | disclosed |
| EP-2051976-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008005569-A2 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286816-A1 | MODULATORS OF METABOLISM AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A1, PC | ADORA2A 1018/4885ADORA1 654/4885CYP2C9 316/4885 |
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | ADORA2A 282/4885ADORA1 290/4885CYP2C9 917/4885 |
| US-20130116237-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | ADORA2A 63/4885ADORA1 61/4885CYP2C9 730/4885 |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | ADORA2A 63/4885ADORA1 61/4885CYP2C9 730/4885 |
| US-20120202790-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | ADORA2A 63/4885ADORA1 61/4885CYP2C9 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.